Arbutus Biopharma Receives FDA Fast Track Designation for Imdusiran in Chronic Hepatitis B Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy ABUS?
Arbutus Biopharma announced that the FDA has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABUS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABUS
Wall Street analysts forecast ABUS stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.600
Low
7.00
Averages
7.00
High
7.00
Current: 4.600
Low
7.00
Averages
7.00
High
7.00
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arbutus Receives FDA Fast Track Designation for Imdusiran
- FDA Fast Track Designation: Arbutus Biopharma announced that its drug imdusiran for chronic hepatitis B has received Fast Track designation from the FDA, which will expedite its development process and enhance review efficiency, thereby positioning the company favorably in the competitive biopharmaceutical market.
- Significant Clinical Trial Results: In clinical trials, imdusiran has successfully achieved functional cure for 10 chronic hepatitis B patients and allowed others to live medication-free, which not only meets urgent patient needs but also demonstrates the drug's potential market value.
- Innovative Technological Advantage: Imdusiran utilizes a novel N-Acetylgalactosamine delivery technology that effectively targets hepatocytes to reduce hepatitis B viral proteins and antigens, providing strong support for the company's leadership position in the treatment field.
- Global Health Impact: With over 250 million people affected by chronic hepatitis B worldwide, the successful development of imdusiran could significantly improve patient quality of life and reduce mortality associated with the disease, highlighting Arbutus's strategic importance in public health.
See More
Arbutus Biopharma Reports Q4 Earnings with Strong Revenue Growth
- Earnings Performance: Arbutus Biopharma reported a Q4 GAAP EPS of -$0.17, missing expectations by $0.13, indicating ongoing challenges in achieving profitability.
- Revenue Surge: The company achieved Q4 revenue of $14.08 million, representing a 128.2% year-over-year increase, significantly exceeding market expectations by $13.47 million, reflecting strong product demand and market performance.
- Financial Position: As of December 2025, Arbutus holds $91.5 million in cash, cash equivalents, and marketable securities, demonstrating robust liquidity that supports future R&D and operational needs.
- Market Dynamics: The settlement between Arbutus and Genevant mitigates major financial risks, while Moderna faces setbacks in its ongoing patent dispute with Arbutus, potentially impacting its competitive position in the market.
See More
Arbutus and Take-Two Options Trading Activity
- Arbutus Options Volume: Arbutus Biopharma Corp (ABUS) has seen an options volume of 10,247 contracts today, representing approximately 1 million underlying shares, which accounts for 47.7% of its average daily trading volume of 2.1 million shares over the past month, indicating heightened market interest in its future performance.
- High Volume Put Options: Within ABUS, the $4 strike put option has traded 2,782 contracts today, equating to about 278,200 shares, reflecting investor expectations of potential declines in the stock, which could influence its price volatility.
- Take-Two Options Volume: Take-Two Interactive Software, Inc. (TTWO) has recorded an options volume of 13,787 contracts today, representing approximately 1.4 million underlying shares, which is 44.9% of its average daily trading volume of 3.1 million shares over the past month, showcasing active trading interest in its stock.
- TTWO High Volume Put Options: The $185 strike put option for TTWO has seen a trading volume of 5,070 contracts today, representing about 507,000 shares, indicating a cautious sentiment among investors regarding the stock's future performance, which may impact its market behavior.
See More
Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares
Settlement Announcement: Moderna has entered into a $2.25 billion settlement with Arbutus and Genevant regarding a vaccine patent dispute, with a payment of $950 million due in Q3 2026.
Stock Market Reaction: Following the settlement news, Moderna's shares rose by 16%, reflecting a shift in investor sentiment from bearish to bullish.
Future Liabilities: The settlement resolves all enforcement actions against Moderna but leaves a contingent liability of up to $1.3 billion if further litigation affirms liability.
Analyst Insights: Analysts view the settlement as a positive development that alleviates uncertainty for Moderna's stock, while maintaining a neutral rating with a price target of $41.
See More
Midday Market Moves: Notable Stock Fluctuations
- CoreWeave Partnership: CoreWeave's stock surged 8% following a multiyear agreement with Perplexity, which will utilize CoreWeave's platform for next-generation inference workloads, enhancing its competitive edge in the cloud market.
- Broadcom Earnings Anticipation: Broadcom shares rose 2% as investors await its fiscal first-quarter earnings report, with analysts projecting earnings of $2.03 per share and revenue of $19.18 billion, indicating strong market confidence in its performance.
- Dow Inc Upgrade Impact: Dow Inc's stock increased by 4% after KeyBanc upgraded its rating from sector weight to overweight, citing that rising oil prices will benefit U.S. ethylene producers, reflecting optimistic market expectations for its profitability.
- Moderna Lawsuit Settlement: Moderna's shares climbed 12% after the company agreed to pay up to $2.25 billion to settle a lawsuit with Arbutus Biopharma and Genevant Sciences over a Covid vaccine patent, demonstrating proactive legal risk management.
See More
Moderna Settles Patent Dispute with Arbutus and Genevant
- Patent Settlement Agreement: Moderna has agreed to pay $950 million to settle a patent dispute with Arbutus Biopharma and Genevant Sciences, removing a significant legal overhang that is expected to boost market confidence in the company.
- Potential Additional Liability: Under the agreement, Moderna may face up to an additional $1.3 billion payment within 90 days depending on the Federal Circuit's ruling, introducing a layer of uncertainty that could impact its future financial performance.
- Positive Analyst Sentiment: Citi analysts believe the deal alleviates negative pressure on the stock, noting that while it is not the best-case scenario, it is better than feared, with William Blair analysts also viewing it as a positive clearing event.
- Reduced Litigation Costs: J.P. Morgan analysts highlight that the maximum $2.3 billion Moderna must pay is significantly lower than the previously estimated $5 billion, demonstrating effective cost control in the settlement that may contribute to the company's future financial stability.
See More
Arbutus Receives FDA Fast Track Designation for Imdusiran
- FDA Fast Track Designation: Arbutus Biopharma announced that its drug imdusiran for chronic hepatitis B has received Fast Track designation from the FDA, which will expedite its development process and enhance review efficiency, thereby positioning the company favorably in the competitive biopharmaceutical market.
- Significant Clinical Trial Results: In clinical trials, imdusiran has successfully achieved functional cure for 10 chronic hepatitis B patients and allowed others to live medication-free, which not only meets urgent patient needs but also demonstrates the drug's potential market value.
- Innovative Technological Advantage: Imdusiran utilizes a novel N-Acetylgalactosamine delivery technology that effectively targets hepatocytes to reduce hepatitis B viral proteins and antigens, providing strong support for the company's leadership position in the treatment field.
- Global Health Impact: With over 250 million people affected by chronic hepatitis B worldwide, the successful development of imdusiran could significantly improve patient quality of life and reduce mortality associated with the disease, highlighting Arbutus's strategic importance in public health.
See More
Arbutus Biopharma Reports Q4 Earnings with Strong Revenue Growth
- Earnings Performance: Arbutus Biopharma reported a Q4 GAAP EPS of -$0.17, missing expectations by $0.13, indicating ongoing challenges in achieving profitability.
- Revenue Surge: The company achieved Q4 revenue of $14.08 million, representing a 128.2% year-over-year increase, significantly exceeding market expectations by $13.47 million, reflecting strong product demand and market performance.
- Financial Position: As of December 2025, Arbutus holds $91.5 million in cash, cash equivalents, and marketable securities, demonstrating robust liquidity that supports future R&D and operational needs.
- Market Dynamics: The settlement between Arbutus and Genevant mitigates major financial risks, while Moderna faces setbacks in its ongoing patent dispute with Arbutus, potentially impacting its competitive position in the market.
See More
Arbutus and Take-Two Options Trading Activity
- Arbutus Options Volume: Arbutus Biopharma Corp (ABUS) has seen an options volume of 10,247 contracts today, representing approximately 1 million underlying shares, which accounts for 47.7% of its average daily trading volume of 2.1 million shares over the past month, indicating heightened market interest in its future performance.
- High Volume Put Options: Within ABUS, the $4 strike put option has traded 2,782 contracts today, equating to about 278,200 shares, reflecting investor expectations of potential declines in the stock, which could influence its price volatility.
- Take-Two Options Volume: Take-Two Interactive Software, Inc. (TTWO) has recorded an options volume of 13,787 contracts today, representing approximately 1.4 million underlying shares, which is 44.9% of its average daily trading volume of 3.1 million shares over the past month, showcasing active trading interest in its stock.
- TTWO High Volume Put Options: The $185 strike put option for TTWO has seen a trading volume of 5,070 contracts today, representing about 507,000 shares, indicating a cautious sentiment among investors regarding the stock's future performance, which may impact its market behavior.
See More
Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares
Settlement Announcement: Moderna has entered into a $2.25 billion settlement with Arbutus and Genevant regarding a vaccine patent dispute, with a payment of $950 million due in Q3 2026.
Stock Market Reaction: Following the settlement news, Moderna's shares rose by 16%, reflecting a shift in investor sentiment from bearish to bullish.
Future Liabilities: The settlement resolves all enforcement actions against Moderna but leaves a contingent liability of up to $1.3 billion if further litigation affirms liability.
Analyst Insights: Analysts view the settlement as a positive development that alleviates uncertainty for Moderna's stock, while maintaining a neutral rating with a price target of $41.
See More
Midday Market Moves: Notable Stock Fluctuations
- CoreWeave Partnership: CoreWeave's stock surged 8% following a multiyear agreement with Perplexity, which will utilize CoreWeave's platform for next-generation inference workloads, enhancing its competitive edge in the cloud market.
- Broadcom Earnings Anticipation: Broadcom shares rose 2% as investors await its fiscal first-quarter earnings report, with analysts projecting earnings of $2.03 per share and revenue of $19.18 billion, indicating strong market confidence in its performance.
- Dow Inc Upgrade Impact: Dow Inc's stock increased by 4% after KeyBanc upgraded its rating from sector weight to overweight, citing that rising oil prices will benefit U.S. ethylene producers, reflecting optimistic market expectations for its profitability.
- Moderna Lawsuit Settlement: Moderna's shares climbed 12% after the company agreed to pay up to $2.25 billion to settle a lawsuit with Arbutus Biopharma and Genevant Sciences over a Covid vaccine patent, demonstrating proactive legal risk management.
See More
Moderna Settles Patent Dispute with Arbutus and Genevant
- Patent Settlement Agreement: Moderna has agreed to pay $950 million to settle a patent dispute with Arbutus Biopharma and Genevant Sciences, removing a significant legal overhang that is expected to boost market confidence in the company.
- Potential Additional Liability: Under the agreement, Moderna may face up to an additional $1.3 billion payment within 90 days depending on the Federal Circuit's ruling, introducing a layer of uncertainty that could impact its future financial performance.
- Positive Analyst Sentiment: Citi analysts believe the deal alleviates negative pressure on the stock, noting that while it is not the best-case scenario, it is better than feared, with William Blair analysts also viewing it as a positive clearing event.
- Reduced Litigation Costs: J.P. Morgan analysts highlight that the maximum $2.3 billion Moderna must pay is significantly lower than the previously estimated $5 billion, demonstrating effective cost control in the settlement that may contribute to the company's future financial stability.
See More
